Exendin-4 peptide analogues as dual GLP-1/GIP receptor agonists

US9789165B2 · kind B2 · utility

Assignee

• Sanofi · FR

Inventors

• Dieter Kadereit · Kelkheim, DE
• Katrin Lorenz · Frankfurt am Main, DE
• Andreas Evers · Frankfurt am Main, DE
• Torsten Haack · Frankfurt am Main, DE
• Michael Wagner · Frankfurt am Main, DE
• Bernd Henkel · Frankfurt am Main, DE
• Martin Lorenz · Frankfurt am Main, DE
• Siegfried Stengelin · Frankfurt am Main, DE

Key dates

• Filing date: Dec 12, 2014
• Grant date: Oct 17, 2017
• Expiry date: Dec 12, 2034

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K14/605
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to exendin-4 derivatives and their medical use, for example in the treatment of disorders of the metabolic syndrome, including diabetes and obesity, as well as reduction of excess food intake.